GlassScriptPhysician profile
Alka Madan
NPI 1528087426
$7,235.48
in general payments reported to CMS, 2019-2025
29 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $233 · 2021: $1,050 · 2022: $1,167 · 2023: $1,633 · 2024: $1,484 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,545 · Education: $24.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,545.36 |
| Education | $24.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,665.54 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $721.77 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $715.37 | 2019-2025 | |
| Janssen Biotech, INC. | $714.58 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $557.00 | 2019-2025 | |
| Galderma Laboratories, L.P. | $435.54 | 2019-2025 | Aklief, Nemluvio, Dysport |
| Lilly USA, LLC | $393.04 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $343.99 | 2021-2025 | Dupixent |
| Pfizer INC. | $234.06 | 2019-2025 | |
| Amgen INC. | $229.75 | 2021-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $196.93 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $181.09 | 2022-2023 | Vtama |
| Allergan, INC. | $169.44 | 2020-2022 | |
| Ucb, INC. | $164.99 | 2021-2025 | Bimzelx |
| Incyte Corporation | $121.99 | 2022-2024 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $83.34 | 2021-2024 | |
| Almirall LLC | $53.77 | 2022-2023 | Klisyri, Seysara |
| Prugen, INC. Pharmaceuticals | $35.00 | 2020 | |
| Merck Sharp & Dohme LLC | $28.54 | 2023 | Keytruda |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.23 | 2024 | Cabtreo |
| Dermira, INC. | $23.07 | 2020 | |
| Arcutis Biotherapeutics, INC. | $21.65 | 2023 | |
| Botanix Sb INC | $20.93 | 2025 | Sofdra |
| Sandoz INC. | $20.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.33 | 2023 | Spevigo |
| Cipher Pharmaceuticals US LLC | $18.58 | 2025 | Natroba, Spinosad |
| Epi Health, LLC | $17.69 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $15.79 | 2024 | |
| Glenmark Therapeutics INC. | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Madan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.